Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. The company’s portfolio targets eye diseases, allergic and inflammatory conditions, cancer, cardiovascular and metabolic diseases, neurological disorders, hematologic conditions, infectious diseases, and rare diseases. Key commercialized products include EYLEA and EYLEA HD for retinal diseases, Dupixent for atopic dermatitis and asthma, Libtayo for non-small cell lung cancer and other solid tumors, Praluent for cardiovascular risk reduction, and Kevzara for rheumatoid arthritis. Regeneron operates the Regeneron Genetics Center to identify therapeutic targets using human genetics. The company maintains manufacturing capabilities in the United States and Ireland and collaborates with partners such as Sanofi and Bayer. Regeneron also engages in gene therapy and cell medicine development, having acquired 2seventy bio and Decibel Therapeutics to expand its pipeline in these areas.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage regeneron.com
Sector Healthcare IR page investor.regeneron.com
Tags
monoclonal antibodies, gene therapy, oncology, ophthalmology, immunology, cardiology, rare diseases, cell therapies, human genetics, biosimilars, EYLEA HD, EYLEA, Dupixent, Libtayo, Praluent, Kevzara, Evkeeza, Regeneron Genetics Center, 2seventy bio, Decibel Therapeutics, Checkmate Pharmaceuticals, Regeneron Cell Medicines, FUJIFILM Diosynth Biotechnologies, Sanofi, Bayer, Intellia
Press page —

Metrics

Valuation  
Market cap $ 101.074B
Market cap (USD) $ 101.074B
P/E 21.17
PEG 16.76
P/BV 3.02
P/S 5.98
P/OCF 20.86
P/FCF 26.42
Dividend yield 0.37%
Turnover / mcap —
Returns  
ROE 14.9%
ROI 13.6%
ROIC 9.3%
Profit margin 31.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 1.3%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 5.9%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 166
Quality score 21.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 14.343B 14.202B 13.117B 12.173B 16.072B 8.497B 7.863B 6.711B 5.872B 4.86B 4.104B 2.82B 2.105B 1.378B 445.824M 459.074M 379.268M 238.457M 125.024M 63.447M 66.193M 174.017M 57.497M 21.988M 21.973M —
Net profit 4.505B 4.413B 3.954B 4.338B 8.075B 3.513B 2.116B 2.444B 1.199B 895.522M 636.056M 348.074M 424.362M 750.269M -221.76M -104.468M -67.83M -82.71M -105.6M -102.337M -95.446M 41.699M -107.458M -124.377M -76.18M -23.215M
Free cash flow 4.081B 3.665B 3.875B 4.425B 6.529B 2.004B 2B 1.812B 1.034B 961.455M 652.847M 410.151M 427.325M -123.952M -198.899M -3.345M -169.548M -123.943M 8.926M 20.264M -35.26M -23.083M -35.789M -144.893M -65.543M -34.405M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 771.87 712.33 878.29 721.49 631.52 483.11 375.48 373.5 375.96 367.09 542.87 410.25 275.24 171.07 55.44 34.04 25 18.36 19.65 20.04 15.89 — — — — —
Price performance 12m 0.08 -0.19 0.22 0.14 0.31 0.29 0.01 -0.01 0.02 -0.32 0.32 0.49 0.61 2.09 0.63 0.36 0.36 -0.07 -0.02 0.26 — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 1.34B 1.54B 1.72B 2.1B 3.11B 6.04B 5.33B 5.67B 6.21B 5.74B
↳ YoY growth +16.6% +14.5% +12.0% +21.8% +48.2% +94.0% -11.7% +6.4% +9.6% -7.6%
↳ 5y CAGR +116.5% +21.0% +17.0% +23.2% +22.0% +35.1% +28.2% +26.9% +24.2% +13.0%
Borrowings, current (USD) — — — 0.00 — — — — — —
Borrowings, non-current (USD) — — — 0.00 1.98B 1.98B 1.98B 1.98B 1.98B 1.99B
Lease liabilities (USD) — — — 714M 717M 720M 720M 808M 954M 987M
Cash and deposits (USD) 535M 813M 1.47B 1.62B 2.19B 2.89B 3.11B 2.73B 2.49B 3.12B
Intangible assets (USD) — — — — — 6.7M 916M 1.04B 1.15B 1.26B
Right-of-use assets (USD) — — — — — — 71.2M 78M 217M 246M
Net debt (borrowings + leases - cash) (USD) — — — -904M 502M -186M -405M 60.6M 451M -145M
Cash flow detail
Operating cash flow (USD) 1.47B 1.31B 2.2B 2.43B 2.62B 7.08B 5.01B 4.59B 4.42B 4.98B
Purchases of property, plant and equipment (USD) -512M -273M -383M -430M -615M -552M -590M -719M -756M -898M
Change in receivables (cash effect) (USD) -144M -363M -269M -473M -1.36B -1.93B 708M -339M -554M 498M
Change in inventories (cash effect) (USD) -150M -314M -388M -336M -529M -494M -697M -272M -620M -275M
Change in payables (cash effect) (USD) 254M -23.2M 210M 445M 119M 866M -138M 599M 735M 737M
Dividends paid (cash effect) (USD) — — — — — — — 0.00 0.00 -370M
Share buybacks (cash effect) (USD) 0.00 0.00 -4.4M -276M -5.85B -1.65B -2.08B -2.24B -2.6B -3.44B
Interest paid (cash effect) (USD) -5.45M -18.7M -22.3M -25M -23.2M -55.8M -53.7M -73.1M -52.6M -41.6M
Income taxes paid (cash effect) (USD) -481M -755M -206M -342M -188M -1.22B -1.5B -870M -743M -1.25B
Share-based compensation (USD) 560M 507M 427M 464M 432M 602M 725M 885M 983M 994M
Operating cash flow before change in receivables (USD) 1.62B 1.67B 2.46B 2.9B 3.97B 9.01B 4.31B 4.93B 4.97B 4.48B
Free cash flow (OCF - PPE - intangibles) (USD) 961M 1.03B 1.81B 2B 2B 6.53B 4.42B 3.88B 3.66B 4.08B
Income detail
Research and development expense (USD) 2.05B 2.08B 2.19B 3.04B 2.74B 2.91B 3.59B 4.44B 5.13B 5.85B
↳ 5y CAGR +31.1% +27.1% +20.5% +19.0% +11.0% +7.2% +11.6% +15.2% +11.1% +16.4%
Total comprehensive income (USD) 874M 1.21B 2.44B 2.15B 3.52B 8.02B 4.13B 4.11B 4.49B 4.59B
Comprehensive income to owners (USD) 874M 1.21B 2.44B 2.15B 3.52B 8.02B 4.13B 4.11B 4.49B 4.59B
Provision for credit losses (USD) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Credit cost ratio (credit losses / average receivables) (%) 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Reported Feb 7, 2019 Feb 7, 2019 Feb 7, 2019 Nov 5, 2020 Feb 8, 2021 Nov 3, 2022 Feb 5, 2024 Feb 4, 2026 Feb 4, 2026 Feb 4, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 2, 2026 at 4:05 PM EST

PDF Version

TARRYTOWN, N.Y., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

  • 2026 Jefferies Global Healthcare Conference in London at 2:00 p.m. GMT (9:00 a.m. ET) on Tuesday, November 17, 2026

  • 9th Annual Evercore Healthcare Conference at 1:45 p.m. ET on Tuesday, December 1, 2026

  • Citi’s 2026 Global Healthcare Conference at 9:40 a.m. ET on Wednesday, December 2, 2026

The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days.

About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.

October 30, 2026 at 6:30 AM EDT

PDF Version

  • Third quarter 2026 revenues increased 36% to $5.1 billion versus third quarter 2025

  • Dupixent® global net sales (recorded by Sanofi) increased 35% to $6.5 billion

  • EYLEA HD® U.S. net sales increased 62% to $699 million

  • Libtayo® global net sales increased 51% to $550 million

  • GAAP EPS increased 35% to $18.45; non-GAAP EPS(a) increased 70% to $20.07

  • Expanded collaboration with Sanofi, adding multiple next-generation, long-acting immunology antibodies; $1.0 billion up-front to be recognized as collaboration revenue in fourth quarter 2026 with potential to receive up to an additional $7.0 billion in future milestones

  • Pasatru™ (garetosmab) approved by FDA for fibrodysplasia ossificans progressiva (FOP)

TARRYTOWN, N.Y., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN) today announced financial results for the third quarter of 2026 and provided a business update.

"This was an outstanding quarter for Regeneron, with Dupixent, EYLEA HD, and Libtayo each achieving record net sales," said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron. "Our pipeline of about 50 product candidates is rapidly advancing. We expect an FDA decision for cemdisiran in generalized myasthenia gravis next month; our Phase 3 programs in multiple myeloma, lymphoma, anticoagulation, and obesity continue to advance; and we have generated encouraging early data in MASH, POTS, and ovarian cancer. Finally, we expanded our alliance with Sanofi to include four Regeneron-invented, next-generation, long-acting antibodies designed to build on the success of Dupixent."

Financial Highlights

| ($ in millions, except per share data) | | Q3 2026 | | Q3 2025 | | % Change |

| Total revenues | | $ | 5,116 | | | $ | 3,754 | | | 36% | |

| GAAP net income | | $ | 1,949 | | | $ | 1,460 | | | 33% | |

| GAAP net income per share - diluted | | $ | 18.45 | | | $ | 13.62 | | | 35% | |

| Non-GAAP net income(a) | | $ | 2,150 | | | $ | 1,287 | | | 67% | |

| Non-GAAP net income per share - diluted(a) | | $ | 20.07 | | | $ | 11.83 | | | 70% | |

| | | | | | | | | | | | |

"We are pleased with our third quarter financial results, which marked our third consecutive quarter of double-digit growth in both revenue and non-GAAP EPS," said Christopher Fenimore, Executive Vice President, Finance and Chief Financial Officer of Regeneron. "Strong commercial execution across our portfolio, together with the anticipated step-up in Sanofi collaboration revenue in the first full quarter following repayment of the Development Balance, drove a 36% increase in total revenues and a 70% increase in non-GAAP EPS, positioning us to deliver one of our strongest years ever."

Business Highlights

Key Pipeline Progress Regeneron has approximately 50 product candidates in clinical development, including a number of marketed products for which it is investigating additional indications. Updates from the clinical pipeline include:

Libtayo (cemiplimab)

  • In August 2026, the Ministry of Health, Labour and Welfare (MHLW) in Japan approved Libtayo as an adjuvant treatment for cutaneous squamous cell carcinoma (CSCC) and for the treatment of metastatic or locally advanced CSCC. These indications are already approved in the United States and European Union (EU).

  • In October 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending the approval of an alternative dosing schedule for Libtayo across all approved indications. The positive opinion supports reducing Libtayo dosing frequency from every three weeks to every six weeks after the first 12 weeks of treatment. The European Commission (EC) is expected to make a final decision in the coming months. There is also a supplemental Biologics License Application (sBLA) under review by the U.S. Food and Drug Administration (FDA), which has a target action date in March 2027.

  • In October 2026, the Company announced longer-term data which showed increasing and clinically meaningful overall survival benefit for Libtayo as an adjuvant treatment for patients with CSCC. The results were presented at the European Society for Medical Oncology (ESMO) 2026 Meeting.

Other Oncology Programs

  • The FDA accepted for review the resubmission of the BLA for Ordspono™ (odronextamab) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), which has a target action date in February 2027.

  • The Company announced that ubamatamab (MUC16 and CD3 bispecific antibody) showed a high rate of durable responses in an initial study in patients with advanced low-grade serous ovarian cancer (LGSOC). The data are from an ongoing Phase 1/2 trial and were presented at the International Gynecologic Cancer Society (IGCS) 2026 Annual Global Meeting. Based on these preliminary trial results, the Company has been enrolling a single-arm, potentially registrational LGSOC trial and is planning to initiate a confirmatory Phase 3 trial in this setting.

Pasatru (garetosmab)

  • In August 2026, the FDA approved Pasatru to reduce formation of new heterotopic ossification lesions and clinician-assessed flare-ups in adults with FOP. A regulatory application is also under review in the EU.

  • The Company announced positive 84-week results from the Phase 3 trial for Pasatru in adults with FOP. These longer-term findings demonstrated sustained efficacy in halting new, rogue bone growth and in significantly reducing disease flare-ups, and were presented at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting.

Other Programs

  • A three-arm, placebo-controlled Phase 3 study was initiated to evaluate cenvacibart (an antibody to Factor XI (catalytic domain)), and amrecibart (an antibody to Factor XI (A2 domain)), individually, for the prevention of venous thromboembolism in patients with a peripherally inserted central catheter (PICC).

  • The Company has an ongoing Phase 1/2 study for its RNAi therapy targeting CIDEB. Interim results from this randomized, placebo-controlled, first-in-human trial in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) showed that a single dose was generally well tolerated and reduced liver fat by approximately 70% on average from baseline at 12 weeks, with effects sustained through 24 weeks of follow-up. The Company plans to present interim results at the American Association for the Study of Liver Diseases (AASLD) Meeting in November 2026 and to initiate a Phase 3 study in metabolic dysfunction-associated steatohepatitis (MASH)/MASLD in the fourth quarter of 2026.

  • The Company plans to report results from the Phase 2 study for baloncibart (NPR1 antagonist antibody) in postural orthostatic tachycardia syndrome (POTS) at the American Autonomic Society (AAS) Meeting in November 2026. Additionally, the Company plans to initiate a Phase 3 study in POTS in the first half of 2027, pending regulatory feedback.

  • The Company announced new results from the Phase 2 COURAGE trial evaluating trevogrumab (myostatin antibody) for its potential to prevent lean mass and muscle loss during GLP-1 receptor agonist-induced weight loss in people living with obesity. The results of the trial were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting.

  • A second Phase 3 study was initiated for REGN1908-1909, an investigational treatment for cat allergy.

Corporate Updates

  • In October 2026, the Company and Sanofi amended their antibody collaboration, adding multiple next-generation, long-acting Regeneron-invented antibodies to the alliance. Under the terms of the agreement, the Company received an up-front payment of $1.0 billion, and is entitled to receive up to an additional $7.0 billion in the aggregate upon the achievement of certain development, regulatory, and sales-based milestones. The companies will equally share development and commercialization costs for the new programs, and, if commercialized, share any future profits equally on a global basis.

  • In October 2026, the Company announced an agreement with the Biomedical Advanced Research and Development Authority (BARDA) to provide additional supply of Inmazeb® for U.S. preparedness against Ebola disease. Under the terms of the agreement, the Company expects to deliver a pre-specified number of treatment doses of Inmazeb each year to the U.S. government beginning in 2027 through 2031.

Third Quarter 2026 Financial Results

Revenues

| ($ in millions) | | Q3 2026 | | Q3 2025 | | % Change |

| Net product sales: | | | | | | | | |

| EYLEA HD - U.S. | | $ | 699 | | | $ | 431 | | | 62% | |

| EYLEA® - U.S. | | | 400 | | | | 681 | | | (41% | ) |

| Total EYLEA HD and EYLEA - U.S. | | | 1,099 | | | | 1,112 | | | (1% | ) |

| Libtayo - U.S. | | | 396 | | | | 219 | | | 81% | |

| Libtayo - ROW* | | | 154 | | | | 146 | | | 5% | |

| Total Libtayo - Global | | | 550 | | | | 365 | | | 51% | |

| Praluent® - U.S. | | | 81 | | | | 67 | | | 21% | |

| Evkeeza® - U.S. | | | 55 | | | | 43 | | | 28% | |

| Lynozyfic® - Global | | | 19 | | | | 1 | | | ** | |

| Other products - Global | | | 1 | | | | — | | | ** | |

| Total net product sales | | | 1,805 | | | | 1,588 | | | 14% | |

| | | | | | | | | |

| Collaboration revenue: | | | | | | | | |

| Sanofi | | | 2,724 | | | | 1,617 | | | 68% | |

| Bayer | | | 267 | | | | 345 | | | (23% | ) |

| Other | | | 10 | | | | 6 | | | 67% | |

| Other revenue | | | 310 | | | | 198 | | | 57% | |

| Total revenues | | $ | 5,116 | | | $ | 3,754 | | | 36% | |

| | | | | | | | | |

| * Rest of world (ROW) |

| ** Percentage not meaningful or greater than 100% |

| |

EYLEA HD U.S. net product sales increased in the third quarter of 2026, compared to the third quarter of 2025, primarily due to higher sales volumes driven by increased demand, partly offset by a lower net selling price.

EYLEA U.S. net product sales decreased in the third quarter of 2026, compared to the third quarter of 2025, primarily due to lower sales volumes as a result of continued competitive pressures and the continued transition of patients to EYLEA HD.

Libtayo U.S. net product sales increased in the third quarter of 2026, compared to the third quarter of 2025, primarily due to higher sales volumes driven by increased demand.

Sanofi collaboration revenue increased in the third quarter of 2026, compared to the third quarter of 2025, due to an increase in the Company's share of profits from the commercialization of antibodies, which were $2.575 billion and $1.456 billion in the third quarter of 2026 and 2025, respectively. The increase in the Company's share of profits from the commercialization of antibodies was driven by higher profits primarily associated with an increase in Dupixent sales. In addition, the Sanofi Development Balance was fully repaid as of the end of the second quarter of 2026 and no longer reduced Sanofi collaboration revenue beginning in the third quarter of 2026.

Refer to Table 4 for a summary of collaboration revenue.

Operating Expenses

| | | GAAP | | % Change | | Non-GAAP**(a)** | | % Change |

| ($ in millions) | | Q3 2026 | | Q3 2025 | | | Q3 2026 | | Q3 2025 | |

| Research and development (R&D) | | $ | 1,795 | | | $ | 1,475 | | | 22% | | | $ | 1,654 | | | $ | 1,350 | | | 23% | |

| Acquired in-process research and development (IPR&D) | | $ | 22 | | | $ | 83 | | | (73% | ) | | * | | | * | | | * | |

| Selling, general, and administrative (SG&A) | | $ | 678 | | | $ | 658 | | | 3% | | | $ | 588 | | | $ | 541 | | | 9% | |

| Cost of goods sold (COGS) | | $ | 322 | | | $ | 281 | | | 15% | | | $ | 246 | | | $ | 227 | | | 8% | |

| Gross margin on net product sales(b) | | | 82% | | | | 82% | | | | | | 86% | | | | 86% | | | |

| Cost of collaboration and contract manufacturing (COCM)(c) | | $ | 252 | | | $ | 241 | | | 5% | | | * | | | * | | | * | |

| Other operating (income) expense, net | | $ | — | | | $ | (10 | ) | | (100% | ) | | * | | | * | | | * | |

| |

| * GAAP and non-GAAP amounts are equivalent as no non-GAAP adjustments have been recorded |

| |

GAAP and non-GAAP R&D expenses increased in the third quarter of 2026, compared to the third quarter of 2025, driven by the advancement of the Company's clinical pipeline and increased manufacturing activity associated with the Company's product candidates.

Other Financial Information

GAAP other income (expense), net decreased in the third quarter of 2026, compared to the third quarter of 2025, primarily due to lower net gains on marketable and other securities.

In the third quarter of 2026, the Company's GAAP effective tax rate (ETR) was 14.7%, compared to 17.2% in the third quarter of 2025. The GAAP ETR for the third quarter of 2025 was negatively impacted by the enactment of the "One Big Beautiful Bill Act" or "OBBBA," including a $45 million charge related to the re-measurement of the Company's U.S. net deferred tax assets. In the third quarter of 2026, the non-GAAP ETR was 15.0%, compared to 13.1% in the third quarter of 2025.

A reconciliation of the Company's GAAP to non-GAAP results is included in Table 3 of this press release.

Capital Allocation

During the nine months ended September 30, 2026, the Company repurchased $2.3 billion of its common stock. As of September 30, 2026, $2.2 billion remained available for share repurchases under the Company's share repurchase programs.

In October 2026, the Company declared a cash dividend of $0.94 per share on the Company's common stock and Class A stock, payable on December 3, 2026 to shareholders of record as of November 20, 2026.

2026 Financial Guidance*

The Company's full year 2026 financial guidance consists of the following components:

| | | 2026 Guidance |

| | | Prior | | Updated |

| GAAP R&D | | $6.500–$6.635 billion | | $6.600–$6.735 billion |

| Non-GAAP R&D(a) | | $5.950–$6.050 billion | | $6.050–$6.150 billion |

| GAAP SG&A | | $2.830–$2.960 billion | | $2.730–$2.860 billion |

| Non-GAAP SG&A(a) | | $2.500–$2.600 billion | | $2.400–$2.500 billion |

| GAAP gross margin on net product sales | | 78%–79% | | Approximately 80% |

| Non-GAAP gross margin on net product sales(a) | | 84%–85% | | Approximately 86% |

| GAAP COCM | | $985 million–$1.035 billion | | Unchanged |

| Non-GAAP COCM(a) | | $970 million–$1.020 billion | | Unchanged |

| Capital expenditures | | $1.030–$1.100 billion | | $1.050–$1.100 billion |

| GAAP effective tax rate | | 13%–14% | | Approximately 14% |

| Non-GAAP effective tax rate(a) | | 14%–15% | | Approximately 15% |

| | | | | |

| * The Company's 2026 financial guidance does not assume the completion of any business development transactions not completed as of the date of this press release |

| |

A reconciliation of full year 2026 GAAP to non-GAAP financial guidance is included below:

| | | Projected Range |

| ($ in millions) | | Low | | High |

| GAAP R&D | | $ | 6,600 | | | $ | 6,735 | |

| Stock-based compensation expense | | | (550 | ) | | | (580 | ) |

| Other | | | — | | | | (5 | ) |

| Non-GAAP R&D(a) | | $ | 6,050 | | | $ | 6,150 | |

| | | | | |

| GAAP SG&A | | $ | 2,730 | | | $ | 2,860 | |

| Stock-based compensation expense | | | (325 | ) | | | (350 | ) |

| Other* | | | (5 | ) | | | (10 | ) |

| Non-GAAP SG&A(a) | | $ | 2,400 | | | $ | 2,500 | |

| | | | | |

| GAAP gross margin on net product sales | | | 80% | | | | 80% | |

| Stock-based compensation expense | | | 1% | | | | 1% | |

| Other** | | | 5% | | | | 5% | |

| Non-GAAP gross margin on net product sales(a) | | | 86% | | | | 86% | |

| | | | | |

| GAAP COCM | | $ | 985 | | | $ | 1,035 | |

| Temporary manufacturing interruption-related costs | | | (15 | ) | | | (15 | ) |

| Non-GAAP COCM(a) | | $ | 970 | | | $ | 1,020 | |

| | | | | |

| GAAP ETR | | | 14% | | | | 14% | |

| Income tax effect of GAAP to non-GAAP reconciling items | | | 1% | | | | 1% | |

| Income tax expense: Shortfall from stock-based compensation | | (<1% | ) | | (<1% | ) |

| Non-GAAP ETR(a) | | | 15% | | | | 15% | |

| | | | | |

| * Includes litigation settlements and other costs |

| ** Includes intangible asset amortization and temporary manufacturing interruption-related costs |

| (a) | This press release uses non-GAAP R&D, non-GAAP SG&A, non-GAAP COGS, non-GAAP gross margin on net product sales, non-GAAP COCM, non-GAAP other income (expense), net, non-GAAP ETR, non-GAAP net income, non-GAAP net income per share, and free cash flow, which are financial measures that are not calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP). These non-GAAP financial measures are computed by excluding certain non-cash and/or other items from the related GAAP financial measure. The Company also includes a non-GAAP adjustment for the estimated income tax effect of reconciling items. A reconciliation of the Company's GAAP to non-GAAP results is included in Table 3 of this press release. The Company makes such adjustments for items the Company does not view as useful in evaluating its operating performance. For example, adjustments may be made for items that fluctuate from period to period based on factors that are not within the Company's control (such as the Company's stock price on the dates share-based grants are issued or changes in the fair value of the Company's investments in equity securities) or items that are not associated with normal, recurring operations (such as acquisition and integration costs). Management uses these non-GAAP measures for planning, budgeting, forecasting, assessing historical performance, and making financial and operational decisions, and also provides forecasts to investors on this basis. With respect to free cash flow, the Company believes that this non-GAAP measure provides a further measure of the Company's ability to generate cash flows from its operations. Additionally, the non-GAAP measures presented are intended to provide investors with an enhanced understanding of the financial performance of the Company's core business operations. However, there are limitations in the use of these and other non-GAAP financial measures as they exclude certain expenses that are recurring in nature. Furthermore, the Company's non-GAAP financial measures may not be comparable with non-GAAP information provided by other companies. Any non-GAAP financial measure presented by the Company should be considered supplemental to, and not a substitute for, measures of financial performance prepared in accordance with GAAP. |

| | |

| (b) | Gross margin on net product sales represents gross profit expressed as a percentage of total net product sales recorded by the Company. Gross profit is calculated as net product sales less cost of goods sold. |

| | |

| (c) | Corresponding reimbursements from collaborators and others for manufacturing product is recorded within revenues. |

| | |

Conference****Call Information

Regeneron will host a conference call and simultaneous webcast to discuss its third quarter 2026 financial and operating results on Friday, October 30, 2026, at 8:30 AM Eastern Time. Participants may access the conference call live via webcast, or register in advance and participate via telephone, on the "Investors and Media" page of Regeneron's website at www.regeneron.com. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay and transcript of the conference call and webcast will be archived on the Company's website for at least 30 days.

About Regeneron

Regeneron is a leading biotechnology company that invents, develops, and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, Regeneron's unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in Regeneron's laboratories. Regeneron's medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using its proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. Regeneron is shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling Regeneron to identify innovative targets and complementary approaches to potentially treat or cure diseases.

October 26, 2026 at 7:00 AM EDT

PDF Version

Updated agreement expands 2020 procurement agreement with BARDA for Regeneron's first-in-class antibody treatment forOrthoebolavirus zairense, adding value of approximately $270 million

TARRYTOWN, N.Y., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it has extended its agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to provide additional supply of Inmazeb® (a three-antibody cocktail of atoltivimab, maftivimab, and odesivimab-ebgn) for U.S. preparedness against Ebola disease. Inmazeb was the first Ebola treatment approved by the U.S. Food and Drug Administration (FDA), indicated specifically for infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to infected mothers**,** and has been administered to hundreds of patients since 2019. In a clinical trial, Inmazeb reduced mortality by approximately 55 percent compared to an active control treatment in patients with low viral load. This agreement continues a partnership that began with BARDA's original procurement of the treatment in 2020.

Under the new agreement, Regeneron expects to deliver additional treatment doses of Inmazeb treatment to the U.S. government through 2031 and receive payment of approximately $270 million.

"Maintaining a ready supply of Inmazeb is exactly the kind of preparedness this country needs for the threats we can already see on the horizon," said Leonard S. Schleifer, M.D., Ph.D., Board Co-Chair, President and Chief Executive Officer of Regeneron. "This extended agreement reflects the strength of our long-standing collaboration with BARDA and our shared commitment to ensuring that at-the-ready medicines are available whenever an Ebola outbreak occurs."

Maftivimab Development Program

Separately, Regeneron’s investigational maftivimab monotherapy is being added to the PARTNERS trial to assess use as a potential treatment in the current Bundibugyo virus disease outbreak

Maftivimab has demonstrated positivein vitroand non-human primate activity against Bundibugyo; preprint data now available

Separate from the Inmazeb procurement agreement, Regeneron is evaluating maftivimab, the most potent virus-neutralizing component of Inmazeb, as a potential treatment for Ebola disease caused by Bundibugyo virus, the orthoebolavirus driving the current outbreak in the Democratic Republic of the Congo (DRC) and for which there are no currently approved treatment options. Maftivimab has demonstrated strong efficacy against Bundibugyo virus in in vitro and non-human primate (NHP) studies conducted with Texas Biomedical Research Institute, supporting its continued development as a monotherapy or combination treatment candidate. These data are now available in preprint on BioRxiv.org and pending peer review publication.

"Inmazeb was created by Regeneron scientists in record time using our proprietary VelociSuite® rapid-response technologies," said George D. Yancopoulos, M.D., Ph.D., Board Co-Chair, President and Chief Scientific Officer of Regeneron. "We are now advancing maftivimab, which has already demonstrated positive results in non-human primates infected with Bundibugyo, so that we can bring another potential Ebola treatment forward as quickly as possible to help in the current outbreak. Regeneron's continued supply of Inmazeb to the U.S. government, our advancement of maftivimab and our partnerships to support frontline response capacity reflect the Company's long-term commitment to infectious diseases preparedness, from the laboratory to the communities most affected by outbreaks."

Based on in vitro and NHP efficacy studies, maftivimab is being added to the PARTNERS (Platform Adaptive Randomised Trial for New and Repurposed Filovirus TreatmentS) clinical trial, which is evaluating potential treatments for Bundibugyo virus disease. PARTNERS is delivered through a global partnership of Ministries of Health, researchers, healthcare workers and international research and non-governmental organizations. The trial has been designed and is coordinated internationally by the Pandemic Sciences Institute, University of Oxford, and is being led nationally in the DRC by theInstitut National de Recherche Biomédicale (INRB), supported by the Institute of Tropical Medicine (ITM), Antwerp. The trial is sponsored by the World Health Organization (WHO) and is made possible with the support of Africa CDC.

Regeneron also continues to support Afya Foundation’s emergency response efforts aimed at safeguarding frontline healthcare workers and strengthening healthcare system resilience during the current outbreak.

About Inmazeb Inmazeb is approved by the U.S. FDA for the treatment of infection caused by Orthoebolavirus zairense (formerly known as Zaire ebolavirus) in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection. Inmazeb was created using Regeneron’s VelocImmune® platform and associated VelociSuite® technologies. The treatment consists of three monoclonal antibodies that help neutralize the Ebola virus by blocking its ability to invade a patient’s cells and/or enlisting other immune cells to target infected cells and remove them from the body.

The safety and efficacy of Inmazeb was established through the 681-patient PALM Trial, which was independently conducted by the WHO, the U.S. National Institutes of Health and the INRB during the 2018 DRC outbreak of Ebola virus. In 2019, as reported in the New England Journal of Medicine, the PALM Trial was stopped early following a pre-specified interim analysis that showed the superiority of Inmazeb in preventing death versus two other investigational treatments.

Inmazeb was approved by the FDA in 2020, and in 2022, WHO published its first guidelines for Ebola virus therapeutics, which strongly recommends the use of Inmazeb for treatment of Ebola virus infection and calls on the global community to engage all possible mechanisms to improve access to life-saving Ebola disease medicines. In November 2023, Inmazeb became the first and only Ebola disease treatment to be prequalified by the WHO, certifying that the medicine meets WHO’s standards for quality, safety and efficacy and is considered “essential.”

Since 2018, Inmazeb has been offered by Regeneron at no cost under a compassionate use protocol to infected persons in countries experiencing an Ebola virus disease outbreak caused by Orthoebolavirus zairense, including the DRC and Guinea. In September 2025, the company committed to donate up to 500 doses of Inmazeb to the WHO for exclusive use by governments of low- and lower-middle income countries that are most at-risk for Ebola disease outbreaks.1 In addition, Regeneron has worked with governments in higher- and middle-income countries to establish Inmazeb stockpiles.

This project has been supported in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), under contract numbers HHSO100201700016C and HHSO100201500013C. The contract and federal funding are not an endorsement of the product or company.

IMPORTANT SAFETY INFORMATION AND INDICATION WARNINGS AND PRECAUTIONS FOR INMAZEB

**Hypersensitivity Reactions Including Infusion-Associated Events:**Hypersensitivity reactions including infusion-associated events have been reported during and post-infusion with INMAZEB. These may include acute, life-threatening reactions during and after the infusion. Monitor all patients for signs and symptoms including, but not limited to, hypotension, chills and elevation of fever, during and following INMAZEB infusion. In the case of severe or life-threatening hypersensitivity reactions, discontinue the administration of INMAZEB immediately and administer appropriate emergency care.

Infusion could not be completed in 1% of subjects who received INMAZEB due to infusion-associated adverse events. The rate of infusion of INMAZEB may be slowed or interrupted if the patient develops any signs of infusion-associated events or other adverse events.

**ADVERSE REACTIONS:**The most common adverse events reported in at least 20% of subjects who received INMAZEB were pyrexia (or elevation in fever), chills, tachycardia, tachypnea and vomiting. The evaluation of adverse events in subjects who received INMAZEB may have been confounded by the signs and symptoms of the underlying Orthoebolavirus zairense infection.

DRUG INTERACTIONS: INMAZEB may reduce the efficacy of live vaccine, therefore, avoid the concurrent administration of a live vaccine during treatment with INMAZEB. The interval between live vaccination following initiation of INMAZEB therapy should be in accordance with current vaccination guidelines. The efficacy of INMAZEB among subjects who reported receipt of a recombinant live vaccine prior to their enrollment in the PALM clinical trial was similar to subjects who did not receive a vaccine.

INDICATION INMAZEB is indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection.

Limitations of Use: The efficacy of INMAZEB has not been established for other species of the Orthoebolavirus and Orthomarburgvirus genera. Orthoebolavirus zairense can change over time, and factors such as emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating Orthoebolavirus zairense strains when deciding to use INMAZEB.

Please see accompanying fullPrescribing Informationfor Inmazeb.

About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases. For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.

Forward-Looking Statements and Use of Digital Media This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements. Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Products”) and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, “Regeneron’s Product Candidates”) and research and clinical programs now underway or planned, including without limitation Inmazeb® (a three-antibody cocktail of atoltivimab, maftivimab, and odesivimab-ebgn) for the treatment of infection caused by Orthoebolavirus zairense (also known as Ebola virus) as well as maftivimab as a potential treatment for Bundibugyo ebolavirus; uncertainty of the utilization, market acceptance, and/or commercial success of Regeneron’s Products (including Inmazeb) and Regeneron’s Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing or any potential regulatory approval of Regeneron’s Products and Regeneron’s Product Candidates (such as maftivimab); the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron’s Product Candidates (such as maftivimab) and new indications for Regeneron’s Products; whether and the extent to which Regeneron will be able to deliver the additional treatment doses of Inmazeb set forth in its agreement with the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services (collectively, the "U.S. Government") discussed in this press release (the "Supply Agreement"), the amount of payments (if any) Regeneron may receive pursuant to the Supply Agreement, and whether the Supply Agreement is terminated by the U.S. Government or otherwise prior to completion; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron’s ability to continue to develop or commercialize Regeneron’s Products and Regeneron’s Product Candidates (such as maftivimab); the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; the ability of Regeneron’s collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron’s Products and Regeneron’s Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron’s Products and Regeneron’s Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron’s Products and Regeneron’s Product Candidates in clinical trials; ongoing regulatory obligations and oversight impacting Regeneron’s Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron’s Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes to drug pricing regulations and requirements and Regeneron’s pricing strategy, including in connection with Regeneron’s April 2026 agreements with the U.S. government; other changes in laws, regulations, and policies affecting the healthcare industry; competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, Regeneron’s Products and Regeneron’s Product Candidates; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron’s agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2025, and its Form 10-Q for the quarterly period ended June 30, 2026. Any forward-looking statements are made based on management’s current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).

Media Contact for Regeneron [email protected]

Investor Contact for Regeneron [email protected]


1 As defined by the World Bank based on gross national income per capita.

Primary Logo

Back to top

Close

You are now leaving Investor.Regeneron.com. The site you are about to visit is maintained by a third party who is solely responsible for its content. We encourage you to read the privacy policy of every website you visit.

Continue

Return to Investor.Regeneron.com

Close

You are now leaving Investor.Regeneron.com to visit another Regeneron website.

Continue

Return to Investor.Regeneron.com

Close

You are now leaving Investor.Regeneron.com. The site you are about to visit is maintained by a third party who is solely responsible for its content. We encourage you to read the privacy policy of every website you visit.

Continue

Return to Investor.Regeneron.com

Close

You are now leaving Investor.Regeneron.com to visit another Regeneron website.

Continue

Return to Investor.Regeneron.com

Company Logo

Cookie Preferences Center

Your Choices

We want to be transparent about the information we collect using cookies and similar technologies (“cookies”) and how it is being used, so you can best exercise your choices about these tools. Because we respect privacy, you can manage cookies that are not essential to delivering our websites securely. Select different category headings to find out more and control which categories are enabled. Disabling some types of cookies may impact your experience online.

Prompts

Regeneron Pharmaceuticals, Inc. (ticker REGN), listed in United States.

ETFs Holding Regeneron Pharmaceuticals, Inc.

ETF Weight in ETF Shares Market value As of
SGRT 6.77% 3,864 $ 3.68M Nov 17, 2026
FMKT 4.86% 502 $ 478.105K Nov 17, 2026
STRN 4.25% 1,125 $ 1.071M Nov 17, 2026
AFOS 3.86% 11,093 $ 10.62M Nov 18, 2026
FCUS 2.63% 2,062 $ 1.964M Nov 17, 2026
PRMR 2.45% 2,813 $ 2.248M Aug 31, 2026
KONG 2.43% 847 $ 528.138K Jun 30, 2026
DIVE 2.38% 1,250 $ 1.191M Nov 17, 2026
JDOC 2.06% 213 $ 204.003K Nov 17, 2026
MEDX 2.06% 630 $ 392.83K Jun 30, 2026
RDVI 1.93% 78,699 $ 75.505M Nov 11, 2026
HELX 1.80% 805 $ 501.95K Jun 30, 2026
LSGR 1.77% 23,839 $ 14.865M Jun 30, 2026
GMOV 1.68% 2,256 $ 1.803M Aug 31, 2026
PVAL 1.61% 283,633 $ 226.645M Aug 31, 2026
RILA 1.50% 828 $ 631.458K Jul 31, 2026
MKTN 1.44% 2,470 $ 1.54M Jun 30, 2026
CSTK 1.41% 3,245 $ 2.475M Jul 31, 2026
FFF 1.39% 116 $ 87.959K Sep 30, 2026
NUGO 1.35% 43,305 $ 33.026M Jul 31, 2026
HRTS 1.34% 929 $ 742.345K Aug 31, 2026
HEQQ 1.16% 355 $ 340.005K Nov 17, 2026
JEPI 1.11% 534,671 $ 512.086M Nov 17, 2026
CGGO 1.08% 132,322 $ 126.023M Nov 16, 2026
FLCV 1.08% 1,880 $ 1.502M Aug 31, 2026
TAX 1.01% 321 $ 256.505K Aug 31, 2026
CVAR 0.99% 556 $ 424.022K Jul 31, 2026
BAMV 0.96% 1,384 $ 1.106M Aug 31, 2026
DSTL 0.91% 30,906 $ 19.271M Jun 30, 2026
FLCC 0.84% 1,394 $ 1.114M Aug 31, 2026
QIDX 0.81% 413 $ 314.966K Jul 31, 2026
LCDS 0.81% 135 $ 129.298K Nov 17, 2026
JOYT 0.79% 978 $ 936.689K Nov 17, 2026
FLCG 0.78% 6,011 $ 4.803M Aug 31, 2026
LVDS 0.74% 925 $ 885.928K Nov 17, 2026
SGLC 0.73% 1,945 $ 1.554M Aug 31, 2026
JEPQ 0.64% 275,345 $ 263.714M Nov 17, 2026
AVIE 0.63% 110 $ 104.764K Nov 16, 2026
LSVD 0.61% 5,194 $ 3.961M Jul 31, 2026
VFVA 0.61% 7,247 $ 5.791M Aug 31, 2026
HELO 0.59% 29,522 $ 28.275M Nov 17, 2026
VFMF 0.52% 6,347 $ 5.072M Aug 31, 2026
JUSA 0.47% 4,316 $ 4.134M Nov 17, 2026
BTAL 0.45% 2,024 $ 1.262M Jun 30, 2026
LGDX 0.44% 640 $ 609.536K Nov 17, 2026
DVAL 0.42% 486 $ 303.04K Jun 30, 2026
INFO 0.40% 4,259 $ 4.069M Nov 13, 2026
MODL 0.38% 6,262 $ 3.905M Jun 30, 2026
FELV 0.37% 19,161 $ 11.948M Jun 30, 2026
FLSP 0.36% 5,493 $ 3.425M Jun 30, 2026
BDVL 0.35% 6,566 $ 6.253M Nov 16, 2026
ENHU 0.35% 34 $ 32.382K Nov 16, 2026
JAVA 0.35% 27,052 $ 25.909M Nov 17, 2026
DFUV 0.34% 55,478 $ 52.77M Nov 12, 2026
FYEE 0.34% 963 $ 734.413K Jul 31, 2026
FELC 0.33% 41,533 $ 25.897M Jun 30, 2026
GPT 0.32% 123 $ 76.695K Jun 30, 2026
DFLV 0.30% 23,930 $ 22.762M Nov 12, 2026
TUGN 0.29% 371 $ 231.333K Jun 30, 2026
CAPE 0.29% 1,101 $ 686.518K Jun 30, 2026
SFTY 0.25% 2,433 $ 1.944M Aug 31, 2026
STOX 0.24% 685 $ 547.37K Aug 31, 2026
DYNF 0.24% 102,723 $ 97.833M Nov 16, 2026
AVSU 0.23% 1,144 $ 1.09M Nov 16, 2026
TVAL 0.22% 2,659 $ 2.532M Nov 17, 2026
XMAG 0.22% 509 $ 484.156K Nov 13, 2026
NBCR 0.21% 2,286 $ 1.827M Aug 31, 2026
TUG 0.21% 118 $ 73.578K Jun 30, 2026
AVLC 0.18% 3,028 $ 2.884M Nov 16, 2026
ACVF 0.17% 345 $ 263.107K Jul 31, 2026
AVUS 0.17% 26,313 $ 25.061M Nov 16, 2026
IALT 0.17% 13,918 $ 13.256M Nov 16, 2026
DFAU 0.15% 20,886 $ 19.867M Nov 12, 2026
DFSU 0.15% 3,647 $ 3.469M Nov 12, 2026
INRO 0.14% 896 $ 853.35K Nov 16, 2026
DFUS 0.14% 31,322 $ 29.793M Nov 12, 2026
LCTU 0.13% 1,537 $ 1.464M Nov 16, 2026
AAUS 0.13% 691 $ 660K Nov 18, 2026
DXUV 0.13% 8,499 $ 8.084M Nov 12, 2026
VSLU 0.12% 1,094 $ 682.153K Jun 30, 2026
DCOR 0.12% 57,342 $ 54.543M Nov 12, 2026
APUE 0.12% 3,768 $ 3.011M Aug 31, 2026
VOXP 0.12% 9 $ 6,863.67 Jul 31, 2026
GDE 0.11% 670 $ 535.384K Aug 31, 2026
DFAC 0.10% 96,411 $ 91.705M Nov 12, 2026
NTSX 0.09% 2,067 $ 1.289M Jun 30, 2026
HCMT 0.09% 697 $ 531.553K Jul 31, 2026
TACU 0.09% 18 $ 17.143K Nov 17, 2026
THRO 0.09% 10,080 $ 9.6M Nov 16, 2026
NTSD 0.08% 45 $ 28.059K Jun 30, 2026
MSLC 0.08% 3,907 $ 3.122M Aug 31, 2026
GSPY 0.06% 411 $ 391.436K Nov 17, 2026
CSHP 0.05% 206 $ 196.194K Nov 16, 2026
RAA 0.05% 469 $ 292.44K Jun 30, 2026
PINK 0.02% 78 $ 74.705K Nov 17, 2026
EBI 0.01% 73 $ 58.333K Aug 31, 2026
NPFE 0.00% 2 $ 1,525.26 Jul 31, 2026
GEW 0.00% 4 $ 3,196.32 Aug 31, 2026
CORO 0.00% 62 $ 58.89K Nov 16, 2026